Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and ...

Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting first-line therapy are follicular lymphoma highlights from ASH 2025.

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma that affects white blood cells called ...

Shared decision-making—balancing clinical data with the patient's personal, logistical, and risk-tolerance factors—is ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases. The indolent ...

Thanks to a clinical trial for follicular lymphoma at MSK, Michael is able to spend time with family, including his granddaughter, Natalia. Retired New York City police officer Michael T. had grown ...

For some people, treating follicular lymphoma involves active surveillance until severe symptoms develop. For others, chemoimmunotherapy, radiation therapy, or targeted treatments may be necessary.

Future studies may look at targeting the CD40 pathway as a potential therapeutic target ORLANDO, DECEMBER 7, 2025 - Researchers at The University of Texas MD Anderson Cancer Center have characterized ...